Afterwork Event: Carve‑Outs in Pharma and Beyond< /strong>
\n📍 \;Campus Biotech\, Geneva
\n📅& nbsp\;Thursday\, October 1\, 2026
\nJoin us for an exclusiv e evening co‑hosted by \;Swiss Healthcare Licensing Group (S wiss HLG) \;and \;Gyrus Capital \;to explore one of the most powerful value creation strategies in healthcare and life sciences: \;carve-outs.
\nBy separatin g non-core assets or businesses into independent companies\, carve-outs ca n unlock hidden value\, sharpen strategic focus\, and create platforms for sustainable growth.
\n\;
\n🎤 \;Keynote Sp eaker:
\n💡 \;
💼
🍸 \;Networking Apéro:
\nContinue t he conversation over drinks and refreshments while connecting with peers f rom Switzerland's healthcare\, biotech\, pharmaceutical\, and investment c ommunities.
\n🕔 \;Schedule:
\n\;
\nEtienne Jornod: Executive Chairman of OM Pharma\, Former Executive Chairman Galenica and Vifor\, Former Chairma n NZZ and Director Alliance Boots (KKR)
\nEtienne Jornod ha s been the Executive Chairman and Co-owner of OM Pharma since October 2020 . Mr Jornod founded Optimus Holding with the goal of buying OM Pharma alon g with other Swiss entrepreneurs and the Turkish pharmaceutical leader Abd i Ibrahim. The ambition is to further expand OM Pharma and invest in R& \;D to exploit the full potential of its bacterial extracts.
\nIn or der to do this\, Mr Jornod stepped down as Executive Chairman of Vifor Pha rma's Board of Directors early 2020\, making a public offer for OM Pharma which was then a Vifor Pharma affiliate. To avoid any conflict of interest \, the sales process was managed by Rothschild. \;
\nMr Jornod s pent all of his career at Galenica-Vifor Group\, were he started as Junior Product Manager at the age of 22. In 1995\, he became Chairman and CEO of the Galenica Group\, which took the name of the Vifor Pharma Group in 201 7. Under his management the Group grew from a wholesaler\, solely reserved for Swiss pharmacists\, to a global group focused on two main activities: Vifor Pharma (Global Speciality Pharma Company) and Galenica Santé (Phar macy Chain with Services and Products). In 2017\, the Vifor Pharma Group s old Galenica Santé on the stock market via an IPO. Both groups were value d at more than CHF14 billion on Mr Jornod’s retirement. For 10 years\, u ntil April 2023\, Mr Jornod was Chairman of the Board of Directors of the NZZ-Mediengruppe. \;During his career\, Mr Jornod has also been a memb er of the board of numerous private and listed companies\, such as Allianc eUnichem (Footsee)\, AllianceBoots (KKR)\, Bieffe Medital\, Bon Appétit a nd Vaudoise.
\nMr Jornod holds a degree in business and economics fr om HEC Lausanne (lic. oec.) and graduated from the Senior Executive Progra m at Stanford University.
\n\;
\nElsa Torchet: Di rector\, Life Sciences\, Strategy and Business Design\, Deloitte< /p>\n
Elsa is a Director in Deloitte’s Life Sciences practice with 10 years of experience working in a mid-size listed company and consulting. S he advises executives on a diverse array of topics\, including growth stra tegy\, transformation\, risk\, and business development\, with a particula r focus on the precision medicine ecosystem. Elsa’s clients span regiona l\, international\, global\, listed organisations\, as well as privately o wned and family businesses. In her advisory role\, Elsa collaborates with her clients to navigate complex challenges\, delivering innovative and hig h-quality services\, and driving strategic market development. \;
\ n\;
\nIgor Heinzer: Partner – Head of Valuation an d Modelling\, Deloitte
\nIgor is a partner in Strategy & \; Transactions with more than 25 years of international experience and le ads the Valuation and Business Modelling practice of Deloitte Switzerland. He has advised emerging growth companies and global leaders across the ph armaceutical\, biotechnology\, medtech\, diagnostics and broader life scie nces sector. His experience spans M&\;A and licensing transactions\, in tellectual property valuation\, growth and scale-up strategies\, fundraisi ng\, capital allocation\, financial and tax reporting\, and performance tr acking. Igor regularly advises corporate development teams\, C-suite execu tives and Boards on the financial and valuation implications of strategic decisions\, investments and disruptive technologies. \;
\n\ ;
\nBecki Morison: CEO\, Essential Pharma
\nB ecki is a seasoned global executive with more than 25 years of experience in the pharmaceutical industry\, spanning commercial leadership\, market a ccess\, and large-scale organisational transformation. She is currently CE O of Essential Pharma\, an international specialty pharma company. Over he r career\, Becki has held senior leadership roles at LEO Pharma and Eli Li lly\, where she led global commercial functions\, major therapeutic franch ises\, and country and regional organisations across Europe\, Asia-Pacific \, and the US. She has a track record of leading businesses through period s of significant strategic change and building high-performing teams acros s markets.
\n\;
\nRobert Watson: Co-founder\, Gyr us Capital
\nDr. Robert Watson is the co-founder of Gyrus C apital\, a Geneva-based\, healthcare-focused private equity firm\, and has over 20 years of investment experience in the pharma and life sciences se ctor. Over his career\, Rob has led healthcare and life sciences investmen ts across Europe\, the US\, and Asia\, holding senior roles at leading inv estment firms in New York\, London\, Geneva\, and Paris\, including as Man aging Director at Altaris Capital Partners.
\n\nBoletos: https://eventf rog.ch/de/p/diverses/carveouts-in-pharma-and-beyond-from-strategy-to-execu tion-7478349360339678853.html URL;VALUE=URI:https://360exp.net/events/33b18d5e-1525-4cca-b56c-06fa8b43cf 3b END:VEVENT END:VCALENDAR